The social security system in Peru is still undergoing significant change, with low social security contributions due to the informal nature of the labor market as most of the workers are self-employed and lack information and valuation within the system. The Comprehensive Health Insurance (SIS) was introduced in 2002 to provide universal cover for essential health services and income security to nationals. Peru enacted the Law of Universal Health Insurance in 2009.

The Peru Employee Benefits research report provides an in-depth industry analysis, information, and insights of the employee benefits in Peru, including an overview of the state and compulsory benefits in Peru, detailed information about the private benefits in Peru, insights on various central institutions responsible for the administration of the different branches of social security and the regulatory framework of the employee benefits in Peru.

The Russia insurance industry research report provides a detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation, and transit insurance. The report specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries. The report also gives insurers access to information on prevailing insurance regulations, and recent and upcoming changes in the regulatory framework, taxation, and legal system in the country. The report also includes the scope of non-admitted insurance in the country.

The Vermont insurance industry research report provides a detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation, and transit insurance. The report specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries. The report also gives insurers access to information on prevailing insurance regulations, and recent and upcoming changes in the regulatory framework, taxation, and legal system in the country. The report also includes the scope of non-admitted insurance in the country.

The Chronic Urticaria clinical trials market is the largest in Asia Pacific, followed by Europe, North America, the Middle East and Africa, and South and Central America. In a country-wise analysis, as of May 2022, China has the highest number of Chronic Urticaria clinical trials, followed by the US, India, Germany, Russia, Japan, Spain, South Korea, France, and Canada. Spain has the highest average patient enrollment in Chronic Urticaria clinical trials.

Germans’ long tradition of saving money is deeply ingrained in the national psyche. Hence, it is not surprising that across investor segments including mass market, mass affluent, and emerging affluent, a significant chunk of wealth is allocated to savings accounts. Despite recent German equity market highs and the possibility to earn greater returns on investments, German mass market investors on average continue to see equities as high-risk investments and avoid them in favor of savings accounts with guaranteed returns. Mass market investors in Germany also allocate the highest share of their average portfolio to current accounts, which further highlights the risk-aversion and capital-preservation attitude of these investors.

TotalEnergies SE (Total), formerly known as Total SA, has been focusing on using artificial intelligence, blockchain, big data, IoT and drones to digitally transform its operations. The annual ICT spending of Total was estimated at $2.0 billion for 2021. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Total is an integrated multinational energy company with operations spanning the entire oil and gas chain from exploring and producing crude oil and natural gas to transporting and refining oil and gas, trading international oil, and marketing petroleum products. The company also produces specialty petrochemicals and power generation with considerable renewable energy operations. The company supplies feedstock to refineries, charters ships, and undertakes trading on various derivative markets, as well as caters to consumers in transportation, automotive, aerospace, energy, housing, and manufacturing industries.

The Lithuania insurance market size was $1.23 billion in 2021. The market is expected to grow at a CAGR of more than 6% from 2021 to 2026.

The Lithuania insurance market research report provides a detailed outlook by product category for the Lithuanian insurance industry. It provides values for key performance indicators such as gross written premium, penetration, premium ceded, profitability ratios, and premium by line of business, during the review period and forecast period. The report also analyzes distribution channels operating in the segment and gives a comprehensive overview of the Lithuanian economy and demographics. Moreover, it provides detailed information on the competitive landscape in the country and includes details of insurance regulations and recent changes in the regulatory structure.

The Curacao and Sint Maarten insurance industry report provide a detailed analysis of the insurance regulations for life, property, motor, liability, personal accident & health, marine, aviation, and transit insurance. The report also specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries. It also gives insurers access to information on prevailing insurance regulations, and recent and upcoming changes in the regulatory framework, taxation, and legal system in the country. Furthermore, it includes the scope of non-admitted insurance in the country.

GlobalData is currently tracking water and sewage construction projects with a total value of $362.4 billion, which includes all projects from the early stages of pre-planning (announcement and study) through to the execution stage. The Middle East & Africa account for the largest share of pipeline value, of water and sewage construction projects, reflecting the region’s increasing dependence on the desalination of seawater, and the recycling of wastewater, for its supply of potable water. The pipeline of projects currently in execution contributes to the highest value followed by pre-execution, planning, and pre-planning. The Projects in the Gulf Cooperation Council countries constitute a significant majority of the MEA’s pipeline, and the Asia-Pacific region records the second-highest value pipeline of water and sewage projects, followed by the Americas and Europe.

The New Zealand online retailing market size was valued at NZD6.3 billion in 2020. The market is projected to grow at a CAGR of more than 9% during the period 2021-2025. The market has steadily grown over the last five years, supported by the rise in smartphone penetration and retailer investment in mobile apps and mobile optimized platforms. However, the COVID-19 outbreak led to more people using the channel in 2020. In New Zealand, online sales of clothing, footwear & accessories segment is expected to exhibit the highest growth. This growth can be attributed to the significant change in consumer lifestyles sparked by COVID-19 with consumers increasingly opting to shop online amid store closures which is expected to continue even after the pandemic.

The global e-commerce market in the consumer goods industry is valued at $355 billion in 2022. The market is expected to grow at a CAGR of more than 9% during the forecast period. As online shopping evolves to provide more nuanced solutions, brands and manufacturers will need to understand the changes in consumer online shopping behaviors. Online engagement intended to drive e-commerce purchases is becoming more sophisticated as consumer interactions increasingly include a wider range of digital tools and elements.

E-commerce has proved to be a vital route to market during the pandemic and has acted as a workaround to many supply chain and distribution challenges. The pivot made by many businesses to provide more online solutions has accelerated online sales growth beyond all predictions in the last couple of years. This has forced a change in strategy for many organizations and, when brand and investment plans are reviewed, businesses will need to appreciate both the challenges and the benefits that e-commerce will provide in the future.

The UAE pharmaceutical market size was valued at $3.5 billion in 2020. The market is expected to grow at a CAGR of more than 7% during the forecast period. The UAE medical devices market size was valued at $2.4 billion in 2021. The market is expected to grow at a CAGR of more than 3% during 2022-2027. The UAE pharmaceutical industry has considerable development potential for international drugmakers, as the second-largest economy among Arab countries, after Saudi Arabia. The trend in market preferences toward generic drugs and other medical products may influence the future trajectory of the UAE pharmaceuticals sector, as enterprises increasingly attempt to produce generics to keep up with current market dynamics.

Protein Tyrosine Phosphatase (EC 3.1.3.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Protein Tyrosine Phosphatase (EC 3.1.3.48) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Protein Tyrosine Phosphatase (EC 3.1.3.48) targeted therapeutics development and features dormant and discontinued projects.

Rhodopsin (Opsin 2 or OPN2 or RHO) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Rhodopsin (Opsin 2 or OPN2 or RHO) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Rhodopsin (Opsin 2 or OPN2 or RHO) targeted therapeutics development and features dormant and discontinued projects.

Ependymoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Ependymoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Venous Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Venous Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.